Kalpana Morparia - Dr Reddys Non-Executive Independent Director

RDY -- USA Stock  

USD 38.01  0.07  0.18%

Ms. Kalpana Morparia serves as NonExecutive Independent Director of Dr. Reddy Laboratories Ltd. Ms. Kalpana Morparia is the Chair person of J.P. Morgan, South and Southeast Asia. Ms. Morparia is a member of J.P. Morgans Asia Pacifi c Management Committee. Prior to joining J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group Companies and was the Joint Managing Director of ICICI Group from 2001 to 2007. She was recognized by several nationaland international media for her role as one of the leading women professionals. Ms. Morparia holds directorship in Hindustan Unilever Limitedand J.P. Morgan Services India Private Limited in India and Philip Morris International Inc. in USA. She is also a member of the Governing Board of Bharti Foundation. A graduate in science and law from Mumbai University, India. Ms. Morparia has served on several committees constituted by the Government of India.
Age: 69  Director Since 2007  MBA    
91 40 4900 2900  http://www.drreddys.com
Morparia is a member of J P Morgan?s Asia Pacifi c Management Committee. Prior to joining J.P. Morgan India, Ms. Morparia served as Vice Chair on the Boards of ICICI Group Companies and was the Joint Managing Director of ICICI Group from 2001 to 2007. She was recognised by several international and national media for her role as one of the leading women professionals. She serves as an Independent Director on the Boards of Philip Morris International Inc., USA, Hindustan Unilever Limited and as a NonExecutive Director on J P Morgan Asset Management India Private Limited and J P Morgan Services India Private Limited. She is also a Member of the Governing Board of Bharti Foundation. She is a graduate in Science and Law from Bombay University.

Management Efficiency

The company has Return on Asset of 5.42 % which means that on every $100 spent on asset it made $5.42 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.08 % implying that it generated $15.08 on every 100 dollars invested.
The company has 811.73M in debt with debt to equity (D/E) ratio of 23.5 . This implies that the company may be unable to create cash to meet all of its financial commitments. Dr Reddys Laboratories has Current Ratio of 1.85 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives


Arthur RyanRegeneron Pharmaceuticals
Sanjay KhoslaZoetis
Willie ReedZoetis
Bonnie BasslerRegeneron Pharmaceuticals
David BullockOrigin Agritech Limited
Christine PoonRegeneron Pharmaceuticals
Elaine UllianVertex Pharmaceuticals Incorpor
Huda ZoghbiRegeneron Pharmaceuticals
William YoungVertex Pharmaceuticals Incorpor
Terrence KearneyVertex Pharmaceuticals Incorpor
Louise ParentZoetis
Gregory NordenZoetis
Bruce SachsVertex Pharmaceuticals Incorpor
Joseph GoldsteinRegeneron Pharmaceuticals
Charles BakerRegeneron Pharmaceuticals
Larry CordellOrigin Agritech Limited
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
Anthony ColesRegeneron Pharmaceuticals
Robert ScullyZoetis
Linda RhodesZoetis
Jacqualyn FousePerrigo Company plc

Entity Summary

Reddys Laboratories Limited operates as an integrated pharmaceutical company worldwide. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India. Dr Reddys operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 21966 people.Dr Reddys Laboratories Ltd (RDY) is traded on BATS Exchange in USA and employs 21,966 people.

Dr Reddys Laboratories Leadership Team

G Prasad, Co-Chairman of the Board, Chief Executive Officer, Managing Director
MARC KIKUCHI, Chief Executive Officer, North America Generics
Hans Hasler, Additional Independent Director
Leo Puri, Non-Executive Independent Director
Sandeep Poddar, Compliance Officer, Company Secretary
Satish Reddy, Co-Chairman of the Board
Kedar Upadhye, IR Contact Officer
Samiran Das, Executive Vice President Head - FTO and GGPM
Sauri Gudlavalleti, Global Head of Integrated Product Development Organization
YUGANDHAR PUVVALA, Global Head of Supply Chain
Amit Biswas, Executive Vice President - Integrated Product Development
Ravi Bhoothalingam, Non-Executive Independent Director
Alok Sonig, Senior Vice President & India Business Head (Generics)
Allan Oberman, Non-Executive Independent Director
J Ramachandran, Executive Vice President-Management Systems and Corporate Initiatives
Prasad Menon, Lead Non-Executive Independent Director
K Rao, Sr. Vice President & Head ? Chemical Technical Operations (CTO)
Abhijit Mukherjee, COO
Anil Namboodiripad, Global Head of Proprietary Products
Saumen Chakraborty, President, Chief Financial Officer and Global Head of ITBPE, Legal & Compliance and FMCRE
SANJAY SHARMA, Global Head of Manufacturing
Shikha Sharma, Non-Executive Independent Director
Sridar Iyengar, Non-Executive Independent Director
Ganadhish Kamat, Executive Vice President and Global Head-Quality
Sripada Chandrasekhar, President, Global Head of HR and Member of Management Council
Omkar Goswami, Non-Executive Independent Director
Erez Israeli, Chief Operating Officer and Global Head of Generics & PSAI
Kalpana Morparia, Non-Executive Independent Director
Bharat Doshi, Non-Executive Independent Director
J Moreau, Non-Executive Independent Director
Raymond Vre, Global Head of Biologics
Raghav Chari, Senior Vice President - Proprietary Products
Bruce Carter, Non-Executive Independent Director
Saunak Savla, IR Contact Officer
Ashok Ganguly, Non-Executive Independent Director
Umang Vohra, Executive Vice President Head - North America Generics
M Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets)
Cartikeya Reddy, Senior Vice President Head - Biologics
Anupam Puri, Non-Executive Independent Director
Archana Bhaskar, Chief Human Resource Officer
Deepak Sapra, Global Head of PSAI

Stock Performance Indicators

Did you try this?

Run Theme Ratings Now


Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased few shares of
few hours ago
Traded for 188.14
Purchased a lot of shares of
few hours ago
Traded for 150.35
Purchased few shares of
few hours ago
Traded for 175.29
Purchased a lot of shares of
few hours ago
Traded for 152.77
Purchased over 300 shares of
few hours ago
Traded for 9.25
Additionally take a look at Your Equity Center. Please also try Headlines Timeline module to stay connected to all market stories and filter out noise. drill down to analyze hype elasticity.
Search macroaxis.com